Skip to main content
Clinical Trials/NCT04729010
NCT04729010
Unknown
Not Applicable

Acupuncture as a Symptomatic Treatment for Anxiety in Parkinson's Disease

Xiamen University0 sites30 target enrollmentOctober 2021

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Parkinson Disease
Sponsor
Xiamen University
Enrollment
30
Primary Endpoint
Change in the Hamilton Anxiety Scale (HAM-A) between the treatment group.
Last Updated
5 years ago

Overview

Brief Summary

This is a single-center, double-blind, placebo-controlled trial to see if acupuncture can safely and effectively manage anxiety in Parkinson's Disease. Eligible subjects will receive either real or sham acupuncture THREE times weekly for a total of SIX weeks.

Registry
clinicaltrials.gov
Start Date
October 2021
End Date
May 2024
Last Updated
5 years ago
Study Type
Interventional
Study Design
Parallel
Sex
All

Investigators

Sponsor
Xiamen University
Responsible Party
Principal Investigator
Principal Investigator

Kim Yun Jin

Associate Professor

Xiamen University Malaysia

Eligibility Criteria

Inclusion Criteria

  • Patients diagnosed with Parkinson's Disease by authorized Neurologist.
  • Patients 40-75 years of age
  • Patients who have significant anxiety symptom
  • Patients must be on a stable medication regimen for the treatment of PD

Exclusion Criteria

  • Patients who have had previous acupuncture within the past SIX months
  • Patients with dementia, depression, or sleep disorder
  • Patients who are currently taking medications known to affect anxiety

Outcomes

Primary Outcomes

Change in the Hamilton Anxiety Scale (HAM-A) between the treatment group.

Time Frame: SIX weeks

The primary outcome measure will be the change between the baseline visit and the SIX-week time point in the Hamilton Anxiety Scale (HAM-A) between the treatment group. Each item is scored on a scale of 0 (not present) to 4 (severe), with a total score range of 0-56, where \<17 indicates mild severity, 18-24 mild to moderate severity, and 25-30 moderate to severe.

Change in the Generalized Anxiety Disorder 7-Item (GAD-7) scale between the treatment group.

Time Frame: SIX Weeks

The primary outcome measure will be the change between the baseline visit and the SIX-week time point in the Generalized Anxiety Disorder 7-Item (GAD-7) scale between the treatment group. Each item is scored on a scale of 0 (not at all) to 3 (Nearly Every Day), with a total score range of 0-56, where \<4 indicates Minimal Anxiety, 5-9 Mild Anxiety, 10-14 Moderate Anxiety, and 15-21 Severe Anxiety.

Secondary Outcomes

  • Change in the Unified Parkinson's Disease Rating Scale between the treatment group.(THREE months)

Similar Trials